natgillin/translations-raw huggingface dataset:
Food does not affect the bioavailability of Irbesartan Hydrochlorothiazide Zentiva. 
Hrana ne utječe na bioraspoloživost lijeka Irbesartan Hydrochlorothiazide Zentiva.
Therefore, the combination of lithium and Irbesartan Hydrochlorothiazide Zentiva is not recommended (see section 4.4). 
Stoga se kombinacija litija i lijeka Irbesartan Hydrochlorothiazide Zentiva ne preporučuje (vidjeti dio 4.4).
Preparations containing lithium should not be taken with Irbesartan Hydrochlorothiazide Zentiva without close supervision by your doctor. 
Pripravci koji sadrže litij ne smiju se uzimati s lijekom Irbesartan Hydrochlorothiazide Zentiva bez pomnog liječničkog nadzora.
Renal impairment and kidney transplantation: when Irbesartan Hydrochlorothiazide Zentiva is used in patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum levels is recommended. 
Oštećena funkcija bubrega i transplantacija bubrega: kad Irbesartan Hydrochlorothiazide Zentiva uzimaju bolesnici s oštećenom funkcijom bubrega, preporučuje se periodički kontrolirati razine kalija, kreatinina i mokraćne kiseline u serumu.
Following oral administration of Irbesartan Hydrochlorothiazide Zentiva, the absolute oral bioavailability is 60-80% and 50-80% for irbesartan and hydrochlorothiazide, respectively. 
Nakon peroralne primjene lijeka Irbesartan Hydrochlorothiazide Zentiva apsolutna oralna bioraspoloživost je 60-80% za irbesartan, odnosno 50-80% za hidroklorotiazid.
You should also tell your doctor: if you are on a low-salt diet if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Irbesartan Hydrochlorothiazide Zentiva) if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal if you are going to have an operation (surgery) or be given anaesthetics if you have changes in your vision or pain in one or both of your eyes while taking Irbesartan Hydrochlorothiazide Zentiva. 
Svog liječnika također trebate obavijestiti: ako ste na dijeti s malim unosom soli ako imate simptome kao što su neuobičajena žeđ, suha usta, opća slabost, omamljenost, grčevi ili bol u mišićima, mučnina, povraćanje ili neuobičajeno brzi otkucaji srca jer oni mogu upućivati na pretjerani učinak hidroklorotiazida (sastojak lijeka Irbesartan Hydrochlorothiazide Zentiva) ako iskusite povećanu osjetljivost kože na sunce s pojavom simptoma sunčanih opeklina (kao što su crvenilo kože, svrbež, oticanje, nastanak mjehurića), a pojavljuju se brže nego što je normalno ako trebate ići na operaciju (kirurški zahvat) ili trebate primiti anestetike ako tijekom uzimanja lijeka Irbesartan Hydrochlorothiazide Zentiva primijetite promjene vida ili bol u jednom ili oba oka.
The recommended dose of Irbesartan Hydrochlorothiazide Zentiva is one tablet a day. 
Uobičajena doza lijeka Irbesartan Hydrochlorothiazide Zentiva je jedna tableta na dan.
Irbesartan Hydrochlorothiazide Zentiva is not indicated in patients with severe hepatic impairment. 
Irbesartan Hydrochlorothiazide Zentiva nije indiciran u bolesnika s teško oštećenom funkcijom jetre.
Potassium-sparing diuretics, potassium supplements or potassiumcontaining salts substitutes should be co-administered cautiously with Irbesartan Hydrochlorothiazide Zentiva (see section 4.5). 
Diuretici koji štede kalij, nadomjesci kalija ili nadomjesci soli koji sadrže kalij moraju se s oprezom istodobno primjenjivati s lijekom Irbesartan Hydrochlorothiazide Zentiva (vidjeti dio 4.5).
Additional information on individual components: in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with Irbesartan Hydrochlorothiazide Zentiva. 
Dodatne informacije o pojedinačnim komponentama lijeka: uz navedene nuspojave kombiniranog lijeka, moguće nuspojave lijeka Irbesartan Hydrochlorothiazide Zentiva mogu biti i one prethodno prijavljene za pojedinačne komponente lijeka.
Based on its pharmacodynamic properties, Irbesartan Hydrochlorothiazide Zentiva is unlikely to affect the ability to drive and use machines. 
Na temelju farmakodinamičkih svojstava, Irbesartan Hydrochlorothiazide Zentiva ne bi trebao utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
Steady-state plasma concentrations are attained within 3 days after initiation of a once-daily dosing regimen. 
Stanje dinamičke ravnoteže koncentracija u plazmi postiže se 3 dana nakon uvođenja doziranja jedanput na dan.
Common: 
sustava:
General: in patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension, azotemia, oliguria, or rarely acute renal failure (see Section 4.5). 
Općenito: u bolesnika čiji vaskularni tonus i funkcija bubrega ovise najviše o aktivnosti reninangiotenzin-aldosteronskog sustava (npr. bolesnici s teškim kongestivnim zatajenjem srca ili postojećom bolešću bubrega, uključujući stenozu bubrežne arterije), liječenje inhibitorima angiotenzin konvertirajućeg enzima ili antagonistima receptora angiotenzina II koji utječu na taj sustav, bilo je povezano s pojavom akutne hipotenzije, azotemije, oligurije i rijetko s pojavom akutnog zatajenja bubrega (vidjeti dio 4.5).
Irbesartan Hydrochlorothiazide Zentiva is a combination of two active substances, irbesartan and hydrochlorothiazide. 
Irbesartan Hydrochlorothiazide Zentiva je kombinacija dvije djelatne tvari, irbesartana i hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide. 
Irbesartan Hydrochlorothiazide Zentiva je kombinacija irbesartana, antagonista receptora angiotenzina II, i hidroklorotiazida, tiazidskog diuretika.
There is no experience regarding the administration of Irbesartan Hydrochlorothiazide Zentiva in patients with a recent kidney transplantation. 
Nema iskustava s primjenom lijeka Irbesartan Hydrochlorothiazide Zentiva u bolesnika kojima je nedavno transplantiran bubreg.
No dosage adjustment is necessary inolder people. 
U starijih osoba nije potrebno prilagođavati dozu.
Furthermore, renal clearance of lithium is reduced by thiazides so the risk of lithium toxicity could be increased with Irbesartan Hydrochlorothiazide Zentiva. 
Nadalje, tiazidi smanjuju renalni klirens litija pa uzimanje lijeka Irbesartan Hydrochlorothiazide Zentiva može povećati rizik od toksičnosti litija.
Irbesartan Hydrochlorothiazide Zentiva should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) (see section 4.3). 
Irbesartan Hydrochlorothiazide Zentiva ne smiju uzimati bolesnici s teško oštećenom funkcijom bubrega (klirens kreatinina <30 ml/min) (vidjeti dio 4.3).
How to take Irbesartan Hydrochlorothiazide Zentiva 
Kako uzimati Irbesartan Hydrochlorothiazide Zentiva
Common side effects (may affect more than 1 in 10 people): nausea/vomiting abnormal urination fatigue dizziness (including when getting up from a lying or sitting position) blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine). 
Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba) mučnina/povraćanje poremećaj mokrenja umor omaglica (uključujući onu koja se javlja nakon dizanja iz ležećeg ili sjedećeg položaja) krvnim pretragama dokazane povišene vrijednosti enzima koji određuje funkciju srca i mišića (kreatin kinaza) ili povišene razine tvari u krvi koje su pokazatelj funkcije bubrega (dušik iz ureje u krvi, kreatinin)
Lithium: the combination of lithium and Irbesartan Hydrochlorothiazide Zentiva is not recommended (see section 4.5). 
Litij: ne preporučuje se kombinacija litija i lijeka Irbesartan Hydrochlorothiazide Zentiva (vidjeti dio 4.5).
Warnings and precautions Talk to your doctor before taking Irbesartan Hydrochlorothiazide Zentiva and if any of the following apply to you: if you get excessive vomiting or diarrhoea if you suffer from kidney problems or have a kidney transplant if you suffer from heart problems if you suffer from liver problems if you suffer from diabetes if you suffer from lupus erythematosus (also known as lupus or SLE) if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure) if you are taking any of the following medicines used to treat high blood pressure: o an ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems. 
Upozorenja i mjere opreza Obratite se svome liječniku prije nego uzmete Irbesartan Hydrochlorothiazide Zentiva i ako se bilo što od sljedećeg odnosi na Vas: ako značajno povraćate ili imate jaki proljev ako imate problema s bubrezima ili ste imali transplantaciju bubrega ako imate srčanih problema ako imate problema s jetrom ako bolujete od šećerne bolesti ako bolujete od eritemskog lupusa (poznat i kao lupus ili SLE) ako bolujete od primarnog aldosteronizma (stanje povezano s visokom proizvodnjom hormona aldosterona, koji uzrokuje zadržavanje natrija u tijelu i, posljedično, povećanje krvnog tlaka) ako uzimate bilo koji od lijekova navedenih u nastavku, koji se koriste za liječenje visokog krvnog tlaka: ACE inhibitor (primjerice enalapril, lisinopril, ramipril), osobito ako imate bubrežne tegobe povezane sa šećernom bolešću. aliskiren.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance) Second and third trimesters of pregnancy (see sections 4.4 and 4.6) Severe renal impairment (creatinine clearance <30 ml/min) Refractory hypokalaemia, hypercalcaemia 
Preosjetljivost na djelatne tvari ili neku od pomoćnih tvari navedenih u dijelu 6.1 ili na druge tvari koje su derivati sulfonamida (hidroklorotiazid je derivat sulfonamida) Drugo i treće tromjesečje trudnoće (vidjeti dijelove 4.4 i 4.6).
You can take Irbesartan Hydrochlorothiazide Zentiva with or without food. 
Irbesartan Hydrochlorothiazide Zentiva se može uzimati s hranom ili bez nje.
There is no clinical experience with Irbesartan Hydrochlorothiazide Zentiva in patients with hepatic impairment. 
Nema kliničkog iskustva s primjenom lijeka Irbesartan Hydrochlorothiazide Zentiva u bolesnika s oštećenom funkcijom jetre.
Therefore, the use of Irbesartan Hydrochlorothiazide Zentiva is not recommended. 
Primjena lijeka Irbesartan Hydrochlorothiazide Zentiva se stoga ne preporučuje.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) andVA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker. 
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) i VA NEPHRON-D (eng. The Veterans Affairs Nephropathy in Diabetes)) ispitivala su primjenu kombinacije ACE inhibitora s blokatorom angiotenzin II receptora.
No dosage adjustment of Irbesartan Hydrochlorothiazide Zentiva is necessary in older people. 
Nije potrebno prilagođavati dozu lijeka Irbesartan Hydrochlorothiazide Zentiva za starije osobe.
How to store Irbesartan Hydrochlorothiazide Zentiva 
Kako čuvati Irbesartan Hydrochlorothiazide Zentiva
Irbesartan Hydrochlorothiazide Zentiva will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough. 
Liječnik će Vam obično propisati Irbesartan Hydrochlorothiazide Zentiva ako Vam dosadašnje liječenje povišenog krvnog tlaka nije osiguralo odgovarajući učinak.
No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is ≥30 ml/min. 
Nije potrebno prilagođavati dozu u bolesnika koji imaju oslabljenu funkciju bubrega, s klirensom kreatinina ≥ 30 ml/min.
Irbesartan Hydrochlorothiazide Zentiva is for oral use. 
Irbesartan Hydrochlorothiazide Zentiva je namijenjen za primjenu kroz usta.
When measured by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg were 100%. 
Na osnovi ambulantnih mjerenja krvnog tlaka, učinci najniže i najviše koncentracije pri primjeni lijeka Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg iznosili su 100%.
Uncommon side effects ( may affect up to 1 in 100 people): diarrhoea low blood pressure fainting heart rate increased flushing swelling sexual dysfunction (problems with sexual performance) blood tests may show lowered levels of potassium and sodium in your blood. 
Manje česte nuspojave (mogu se javiti u manje od 1 na 100 osoba) proljev nizak krvni tlak nesvjestica ubrzani otkucaji srca crvenilo praćeno osjećajem vrućine oticanje seksualna disfunkcija (problemi sa seksualnom izvedbom) krvne pretrage mogu pokazati smanjene vrijednosti kalija i natrija u krvi Ako Vam neka od navedenih nuspojava uzrokuje tegobe, obratite se svome liječniku.
Severe hepatic impairment, biliary cirrhosis and cholestasis The concomitant use of Irbesartan Hydrochlorothiazide Zentiva with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73 m²) (see sections 4.5 and 5.1). 
Teško oštećenje funkcije jetre, bilijarna ciroza i kolestaza Istodobna primjena lijeka Irbesartan Hydrochlorothiazide Zentiva s lijekovima koji sadrže aliskiren kontraindicirana je u bolesnika sa šećernom bolešću ili oštećenjem bubrega (GFR < 60 ml/min/1,73 m2) (vidjeti dijelove 4.5 i 5.1).
The use of Irbesartan Hydrochlorothiazide Zentiva during breast feeding is not recommended. 
Ne preporučuje se upotreba lijeka Irbesartan Hydrochlorothiazide Zentiva tijekom dojenja.
Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is recommended when Irbesartan Hydrochlorothiazide Zentiva is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics). 
Lijekovi na koje utječu poremećaji razine kalija u serumu: pri istodobnoj primjeni lijeka Irbesartan Hydrochlorothiazide Zentiva i drugih lijekova na čije djelovanje utječu poremećaji kalija (primjerice glikozidi digitalisa, antiaritmici) preporučuje se periodičko praćenje razine kalija u serumu.
Irbesartan Hydrochlorothiazide Zentiva contains lactose. 
Irbesartan Hydrochlorothiazide Zentiva sadrži laktozu.
Lietuva Zentiva, k.s. 
Slovenija Zentiva, k.s.
The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3350, red, yellow and black ferric oxides, pregelatinized starch, carnauba wax. 
Drugi sastojci su laktoza hidrat, mikrokristalična celuloza, umrežena karmelozanatrij, hipromeloza, silicijev dioksid, magnezijev stearat, titanijev dioksid, makrogol 3350, crveni, žuti i crni željezov oksid, prethodno gelirani škrob, karnauba vosak.
Anaphylactic reaction including anaphylactic shock Table 3: Adverse reactions reported with the use of hydrochlorothiazide alone 
Tablica 3. Nuspojave prijavljene pri primjeni samo hidroklorotiazida
If you are taking an ACE-inhibitor or aliskiren (see also information under the headings “Do not take Irbesartan Hydrochlorothiazide Zentiva” and “Warnings and precautions”). 
“Nemojte uzimati Irbesartan Hydrochlorothiazide Zentiva” i “Upozorenja i mjere opreza“).
The other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, macrogol 3000, red and yellow ferric oxides, carnauba wax. 
Drugi sastojci su laktoza hidrat, mikrokristalična celuloza, umrežena karmelozanatrij, hipromeloza, silicijev dioksid, magnezijev stearat, titanijev dioksid, makrogol 3000, crveni i žuti željezov oksid, karnauba vosak.
Each film-coated tablet contains 38.5 mg of lactose (as lactose monohydrate). 
Jedna filmom obložena tableta sadrži 38,5 mg laktoze (u obliku laktoze hidrata).
NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets. 
NAZIV LIJEKA Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložene tablete
Thiazide diuretic-associated azotemia may occur in patients with impaired renal function. 
U bolesnika s oštećenom funkcijom bubrega može se pojaviti azotemija povezana s uzimanjem tiazidskih diuretika.
Each film-coated tablet of Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg contains 300 mg irbesartan and 25 mg hydrochlorothiazide. 
Jedna Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložena tableta sadrži 300 mg irbesartana i 25 mg hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. 
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tablete dostupne su u blister pakiranjima od 14, 28, 56 ili 98 tableta.
However, in patients with mild to moderate renal impairment (creatinine clearance ≥30 ml/min but <60 ml/min) this fixed dose combination should be administered with caution. 
Međutim, kombinaciju fiksne doze treba oprezno primjenjivati u bolesnika koji imaju blago do umjereno oštećenu funkciju bubrega (klirens kreatinina ≥ 30 ml/min, ali < 60 ml/min).
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg tablets are supplied in blister packs of 14, 28, 56 or 98 tablets. 
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg tablete dostupne su u blister pakiranjima od 14, 28, 56 ili 98 tableta.
A total of 697 patients were randomized in a 2:1 ratio to either irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to irbesartan 150 mg and systematically force-titrated (before assessing the response to the lower dose) after one week to irbesartan/hydrochlorothiazide 300 mg/25 mg or irbesartan 300 mg, respectively. 
Nakon jednog tjedna doze su sustavno forsirano titrirane (prije procjene odgovora na nisku dozu) na irbesartan/hidroklorotiazid 300 mg/25 mg odnosno irbesartan 300 mg.
(It is also better to avoid Irbesartan Hydrochlorothiazide Zentiva in early pregnancy - see pregnancy section) if you have severe liver or kidney problems if you have difficulty in producing urine if your doctor determines that you have persistently high calcium or low potassium levels in your blood if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren. 
Nemojte uzimati Irbesartan Hydrochlorothiazide Zentiva ako ste alergični na irbesartan ili neki drugi sastojak ovoga lijeka (naveden u dijelu 6.) ako ste alergični na hidroklorotiazid ili neki drugi lijek koji je derivat sulfonamida ako ste trudni više od 3 mjeseca (preporučuje se također izbjegavati Irbesartan Hydrochlorothiazide Zentiva i u ranoj trudnoći - vidjeti dio o trudnoći) ako imate teških problema s jetrom ili bubrezima ako imate poteškoća sa stvaranjem urina ako liječnik utvrdi da imate stalno povišenu razinu kalcija ili nisku razinu kalija u krvi ako imate šećernu bolest ili oštećenu bubrežnu funkciju i liječite se lijekom za snižavanje krvnog tlaka koji sadrži aliskiren
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg tablets irbesartan/hydrochlorothiazide NAME OF THE MARKETING AUTHORISATION HOLDER Zentiva k.s. 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NAZIV LIJEKA Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg tablete irbesartan/hidroklorotiazid NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Zentiva k.s. ROK VALJANOSTI
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg tablets irbesartan/hydrochlorothiazide NAME OF THE MARKETING AUTHORISATION HOLDER Zentiva k.s. 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NAZIV LIJEKA Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tablete irbesartan/hidroklorotiazid NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Zentiva k.s. ROK VALJANOSTI
Each tablet of Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide. 
Jedna Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg tableta sadrži 150 mg irbesartana i 12,5 mg hidroklorotiazida.
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. 
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložene tablete dostupne su u blister pakiranjima od 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tabletatableta.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS NAME OF THE MEDICINAL PRODUCT Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide NAME OF THE MARKETING AUTHORISATION HOLDER Zentiva k.s. 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP NAZIV LIJEKA Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Zentiva k.s. ROK VALJANOSTI
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide 
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg filmom obložene tablete irbesartan/hidroklorotiazid
No dosage adjustment of Irbesartan Hydrochlorothiazide Zentiva is necessary in patients with mild to moderate hepatic impairment (see section 4.3). 
Za bolesnike s s blagim ili umjerenim oštećenjem funkcijejetre nije potrebna prilagodba doze lijeka Irbesartan Hydrochlorothiazide Zentiva (vidjeti dio 4.3).
EU/1/06/377/001 - 14 tablets EU/1/06/377/002 - 28 tablets EU/1/06/377/003 - 56 tablets EU/1/06/377/004 - 56 x 1 tablets EU/1/06/377/005 - 98 tablets 
EU/1/06/377/001 - 14 tableta EU/1/06/377/002 - 28 tableta EU/1/06/377/003 - 56 tableta EU/1/06/377/004 - 56 x 1 tableta EU/1/06/377/005 - 98 tableta
EU/1/06/377/006 - 14 tablets EU/1/06/377/007 - 28 tablets EU/1/06/377/008 - 56 tablets EU/1/06/377/009 - 56 x 1 tablets EU/1/06/377/010 - 98 tablets 
EU/1/06/377/006 - 14 tableta EU/1/06/377/007 - 28 tableta EU/1/06/377/008 - 56 tableta EU/1/06/377/009 - 56 x 1 tableta EU/1/06/377/010 - 98 tableta
• Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone; 
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati lijekom Irbesartan Hydrochlorothiazide Zentiva 300 mg/12,5 mg.
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. 
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12,5 mg filmom obložene tablete dostupne su u blister pakiranjima od 14, 28, 30, 56, 84, 90 ili 98 filmom obloženih tableta.
EU/1/06/377/017 - 14 tablets EU/1/06/377/018 - 28 tablets EU/1/06/377/031 - 30 tablets EU/1/06/377/019 - 56 tablets EU/1/06/377/020 - 56 x 1 tablets EU/1/06/377/021 - 84 tablets EU/1/06/377/032 - 90 tablets EU/1/06/377/022 - 98 tablets 
EU/1/06/377/017 - 14 tableta EU/1/06/377/018 - 28 tableta EU/1/06/377/031 - 30 tableta EU/1/06/377/019 - 56 tableta EU/1/06/377/020 - 56 x 1 tableta EU/1/06/377/021 - 84 tableta EU/1/06/377/032 - 90 tableta EU/1/06/377/022 - 98 tableta